A recent publication confirmed M-402 was a broad, multi-targeting drug in vivo and one of its very interesting effects relevant to pancreatic cancer invasion/metastasis was on the levels of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-3 (TIMP3); it reduced the former and increased the latter (104). This evidence concerns the gene MMP1 and familial pancreatic carcinoma.